StockNews.AI
ALT
StockNews.AI
180 days

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

1. Altimmune schedules Q4 and full year 2024 earnings announcement on Feb 27, 2025. The report could set near-term expectations. 2. A conference call at 8:30 am ET will provide a business update. It may offer insights into operational progress. 3. The company is advancing a GLP-1/glucagon dual receptor agonist, pemvidutide, for obesity and MASH. This could impact future growth.

Earnings
-5.6%Current Return
VS
-1.87%S&P 500
$6.7802/20 07:36 AM EDTEvent Start
$6.402/21 02:19 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

This is an expected earnings announcement with no new surprises. Historically, scheduled earnings calls typically drive modest price volatility rather than dramatic shifts.

How important is it?

Earnings announcements are critical to investor decision-making and near-term price action, even if the news is routine.

Why Short Term?

Earnings releases tend to affect stock prices immediately around the reporting period, as seen in similar biopharma cases.

Related Companies

NVOLLY
February 20, 2025 07:30 ET  | Source: Altimmune, Inc GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. Altimmune management will host a conference call at 8:30 am E.T. on February 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months. About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter Company Contact:Greg WeaverChief Financial OfficerPhone: 240-654-1450ir@altimmune.com Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.com Media Contact:Danielle CanteyInizio Evoke, BiotechPhone: 619-826-4657Danielle.cantey@inizioevoke.com This press release was published by a CLEAR® Verified individual.

Related News